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Background: We hypothesized that diagnostic laparoscopy (DL) was feasible for the evaluation of patients with
peritoneal carcinomatosis (PC) undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
(CRS + HIPEC).
Methods: A retrospective review of PC patients treated from January 2010 to April 2013 was conducted. Data on
tumor characteristics, treatment details and survival outcomes were extracted and analyzed.
Results: Of the 101 PC patients (mean age 52.9 ± 14.1 years), 73 diagnostic laparoscopies DL (61 concurrent with
CRS + HIPEC) were performed in 70 patients whereas 31 patients underwent direct exploratory laparotomy (EL).
Complete laparoscopic assessment was possible in 63 cases (86.3%), resulting in 18 exclusions (27.7%) while 10
cases were converted to open due to inadequate laparoscopic visualization. Subsequently, CRS + HIPEC was
performed in 85.4% (of 55 selected for HIPEC, DL) versus 74.2% (EL, P value = 0.20). Among those excluded from
HIPEC at the initial operation, delayed HIPEC after conversion chemotherapy was achieved in 6 (of 11 with
extensive disease, DL). The incidence of grade 3 to 5 complications was 0% DL versus 10% EL (P value = 0.2). There
were no port site recurrences at mean follow up of 9.1 ± 8 months.
Conclusions: Laparoscopy is a feasible technique for selecting patients with PC for CRS + HIPEC, and can help
select patients for conversion chemotherapy in the setting of high peritoneal carcinomatosis index (PCI) score.
Keywords: Peritoneal neoplasms, regional perfusion, chemotherapy, postoperative complications, surgical
procedures, HIPEC, staging, laparoscopyBackground
Peritoneal carcinomatosis (PC) represents an advanced
stage of many cancers and is associated with poor
survival rates [1-5]. Cytoreductive surgery (CRS) with
hyperthermic intraperitoneal chemotherapy (HIPEC)
was introduced in an attempt to improve the prognosis
of these patients and incorporates surgical removal of all
visible disease followed by chemical destruction of
microscopic disease through chemoperfusion [6].* Correspondence: kturaga@mcw.edu
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article, unless otherwise stated.The most validated predictors of outcome in patients
undergoing CRS +HIPEC are preoperative tumor bur-
den measured in terms of the peritoneal carcinomatosis
index (PCI) and completeness of cytoreduction (CC)
[7-10]. Patients undergoing CRS + HIPEC in which sur-
gery achieved complete or near complete cytoreduction
(CC-0 or CCR-1) were shown to have significantly
greater survival benefit over those who did not [7,9,11].
Survival analyses studies have shown that patients with
PCI scores less than 19 (colorectal) and 10 (gastric)
benefit most from CRS +HIPEC, facilitating the use of
these scores as general cut-offs for excluding patients
from this morbid procedure [12-15]. Exclusion ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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therapeutic laparotomy) is undesirable and may impede
the timely enrollment of patients into alternate therapies
[16]. Therefore, the role of preoperative imaging in CRS
+HIPEC is to filter out patients with very high volume
disease or no carcinomatosis. Despite advancements in
cross-sectional imaging, the proportion of patients
excluded at direct exploratory laparotomy for CRS +
HIPEC is high (20 to 40%) [17,18].
Diagnostic laparoscopy prior to resection is widely
used in hepatopancreaticobiliary and colorectal cancer
and has been shown to be effective in excluding un-
necessary laparotomy associated with higher morbidity
[19,20]. The laparoscopy could be done concomitantly at
the time of planned resection or as a separate staging
procedure [19]. In addition, this may permit earlier en-
rollment of these patients into palliative or neoadjuvant
therapy with potential impact on survival [16]. However,
there is a paucity of data on the use of laparoscopy in
the evolving field of cytoreductive surgery [21]. Since PC
represents an advanced stage of cancer, visualization
may be difficult due to adhesions from the cancer or
prior surgical procedures. Additionally, there is poten-
tially increased risk of complications such as visceral
perforation in the setting of PC. The hypothesis for the
present study was that laparoscopic evaluation is feasible
for the evaluation of patients with peritoneal carcinoma-
tosis selected for CRS +HIPEC.
Methods
A retrospective review of patients treated for peritoneal
carcinomatosis at the The Froedtert & the Medical Col-
lege of Wisconsin’s Regional Cancer Therapy Program
between January 2010 and April 2013 was performed
after approval by the Institutional Review Board (IRB).
Demographic information of patients who underwent
laparoscopic/laparotomy evaluation for CRS + HIPEC
was extracted. Patients who had multiple HIPECS as
well as those who underwent CRS outside and were
referred to our institute for further management were
excluded from the study. Data on tumor characteris-
tics, operative details, hospital course, and morbidity
(Clavien-Dindo classification) and survival outcomes
were extracted and entered into a pre-specified data
extraction sheet. The length of the hospital stay was
calculated from the date of the surgical procedure to the
date of discharge. The follow-up information current
with 4 April 2013 (date of IRB approval) was captured.
All patients referred for treatment under the program
underwent routine preoperative computerized tomog-
raphy (CT) imaging at the institute when recent outside
scans were unavailable. If outside scans were available,
these were reviewed by radiologists at the institute. Pre-
operative work-up also included all blood work-ups andrelevant tumor markers. Patients selected for CRS +
HIPEC by imaging routinely underwent laparoscopic
staging prior to laparotomy. However, patients were se-
lected for direct laparotomy if they had recent surgical
evaluation prior to their referral to our program and the
disease appeared amenable for CRS + HIPEC based on
operative notes and cross sectional imaging. Patients
were classified as extensive disease for exclusion from
CRS +HIPEC for PCI scores higher than 11 for gastric
cancer and 19 for colorectal and non-gastric primaries.
In addition, patients with no suspicion for peritoneal
carcinomatosis were also excluded from CRS + HIPEC.
Technique for diagnostic laparoscopy
The site of first port placement during diagnostic lapa-
roscopy (DL) was decided at the surgeon’s discretion
based on imaging and clinical findings of the patient. The
preferred technique for first creation of pneumoperito-
neum was via the optical access technique in the left
upper quadrant. In others, a Hasson’s technique was used
to establish pneumoperitoneum. After ruling out signifi-
cant adhesions at the anterior abdominal wall, systematic
visual examination of the abdomen was performed to
generate the PCI score (complete laparoscopy) [7,22].
Systematic examination of the abdomen was then
performed including special attention to peri-splenic,
peri-hepatic, pelvic, omental bursa and bowel.
Technique for hyperthermic intraperitoneal
chemotherapy
After cytoreduction, HIPEC was performed using the
closed technique and dosing of therapy was based on
standard published consensus guidelines [23].
Subsequent management
Patients excluded from CRS + HIPEC were either en-
rolled into a chemotherapy program with plan for future
CRS +HIPEC or discharged to hospice or home care.
The first post-operative visit after CRS +HIPEC was
planned at 6 weeks. Subsequent visits were planned to
take place every 3 months for 2 years and subsequently,
every 6 months for 3 years. The visits included physical
examinations and lab chemistries including basic
hematological parameters, blood chemistry, and tumor
markers as appropriate. Imaging follow-up was
performed using CT scans for the majority of the
patients. Magnetic resonance imaging (MRI) and posi-
tron emission tomography (PET) scans were used in
some patients, but were not routine. The most recent
images were reviewed at every visit.
Statistical analyses
Statistical calculations were performed with STATA soft-
ware Version 12.1 (StataCorp, Texas, USA). Continuous
Table 1 Baseline characteristics and outcomes of patients
treated for peritoneal carcinomatosis (N = 101)
Characteristic Mean (SD) Frequency
n (%)












Grade of primary tumor (n = 85)
Grade 1 (Well differentiated) 36 (42.9)
Grade 2 (Moderately differentiated) 23 (27.4)
Grade 3 (Poorly differentiated/signet ring) 25 (29.8)
Preoperative imaging
Computed tomography (CT) scan 89 (88.1)
Magnetic resonance imaging (MRI) scan 41 (40.6)
Positron emission tomography (PET) scan 62 (69.7)
Intraoperative PCI score (n = 74) 15.5 (11.7)
HIPEC completed 73 (72.3)




Length of stay 11.3 (9.1)
Grade 3 to 5 complications 15 (20.5)
Chemotherapy received 46 (45.5)
Before CRS 16 (34.8)
After CRS 19 (41.3)
Both before and after CRS 11 (23.9)
Patients alive and under follow up 82 (81.2)
Status at last office visit (n = 82)
No disease 31 (37.8)
Stable disease 24 (29.3)
Progressive disease 27 (32.9)
CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy;
PCI, peritoneal carcinomatosis index.
Jayakrishnan et al. World Journal of Surgical Oncology 2014, 12:270 Page 3 of 7
http://www.wjso.com/content/12/1/270data are summarized as mean and standard deviation.
Comparison was performed using Student’s t-test for
continuous data. Categorical variables were expressed as
valid percentages and compared using the chi-squared
test or Fisher’s exact test as appropriate. The survival
analysis was performed using Kaplan-Meier plots with
log-rank analyses. Alpha was fixed at 0.05 for statistical
significance.
Results
The baseline data and outcomes from CRS +HIPEC for
the 101 patients studied are represented in Table 1. The
most prevalent primary was appendiceal (47.5%),
followed by colorectal (33.7%) and gastric (6.9%). The
presentation of peritoneal carcinomatosis was synchron-
ous in 22 (21.8%) and metachronous in 79 (78.2%)
patients.
Laparoscopic evaluation (DL) was performed 73 times
(12 as a separate procedure and 61 concurrent with
planned CRS + HIPEC) in 70 patients, whereas 31 pa-
tients were selected for direct exploratory laparotomy
(EL). Primary tumor resection prior to CRS was per-
formed in 78 patients (77.2%) overall: 56 (80.0%) in the
DL group versus 22 (71.0%) receiving EL, P value =
0.318. The respective median intervals to second surger-
ies were 11.0 (interquartile range (IQR) 4.8 to 30.3)
months for DL versus 19.8 (11.0 to 50.4) months for EL.
Laparoscopy outcomes
The technical details and outcomes of the DL, stratified
by the timing of the procedure, are described in Table 2
and represented in Figure 1. The DL entry technique
was optical trocar in 68.5% and Hasson trocar in 30.1%
of the procedures. The left subcostal region was the fa-
vored site of entry in 60.3%, while a midline periumbili-
cal incision was used in 39.7% of the procedures.
Complete laparoscopic evaluation was possible in 63
cases (of 73, 86.3%) with 18 (of 73, 27.7%) patients being
excluded from laparotomy for CRS + HIPEC. The reason
for exclusion was extensive disease (high PCI) in 11
cases and absence of carcinomatosis in 7. Laparoscopic
CRS +HIPEC was performed in nine patients, with all
patients achieving CC0 cytoreduction and successful
completion of HIPEC. Of the 46 patients who under-
went laparotomy (4 with a separate laparoscopy and 42
with a concurrent laparoscopy), 38 were selected for
CRS +HIPEC. HIPEC was not performed in six patients
with extensive disease (who underwent resection of
primary and cytoreduction without HIPEC) and two pa-
tients with no carcinomatosis (cases that were inad-
equately visualized in laparoscopy due to adhesions,
these were converted to open). Therefore, CRS + HIPEC
was successfully performed in 85.4% (DL, 47 of 55 not
excluded by laparoscopy) compared to 74.2% (23 of 31,P value = 0.20) in the EL group (Figure 2). The incidence
of Clavien-Dindo grade 3 to 5 complications among
those excluded from HIPEC were 0% with DL versus
10% with EL (P value = 0.2).
Table 2 Technical details and outcomes of diagnostic laparoscopy (DL) stratified by the timing of the procedure
with respect to planned laparotomy for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
(CRS + HIPEC)a
Characteristic Procedure done concurrently with
planned laparotomy for CRS + HIPEC
(n = 61)
Procedure done separately
prior to laparotomy for CRS +
HIPEC (N = 12)
Entrance technique
Visual entry system 43 (70.5) 8
Hasson trocar 18 (29.5) 4
Site entry
Left upper quadrant 38 (62.3) 6
Midline periumbilical 23 (37.7) 6
Laparoscopy converted to open (inadequate visualization due
to adhesions)
10 (16.4) 0
Excluded from laparotomy for CRS + HIPEC after adequate evaluation 10 (19.6) 8
Reason for exclusion
Extensive disease 5 6
No carcinomatosis 5 2
Completed HIPEC 44 (86.3) 3 (1 Patient underwent CRS only
due to poor functional status)
Open HIPEC 35 3
Laparoscopic HIPEC 9 0
Excluded from HIPEC at laparotomy (n = 42: 32 cases selected after





No carcinomatosis (Cases converted from laparoscopy due to
inadequate evaluation)
2
Delayed HIPEC for those excluded at laparoscopy 2 3
aTwo patients underwent both concurrent and separate DL.
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excluded from CRS +HIPEC by laparoscopy, 5 received
delayed CRS +HIPEC following systemic chemotherapy
and down-staging of the disease. At a mean follow-up of
9.1 ± 8 months, 82 patients were alive. At the latest
office visit, 31(37.8%) had no disease while 24(29.3%)
had stable disease. Progressive disease was detected in
27(32.9%) patients. There was no port-site recurrences
at current follow-up.
Discussion
CRS +HIPEC is an evolving treatment option for treat-
ment of patients with peritoneal carcinomatosis and has
been shown to significantly improve survival in multiple
studies [11,24-26]. The present study demonstrates the
feasibility and safety of laparoscopy in the treatment
paradigm of patients with suspected peritoneal disease.
The maximum impact of the laparoscopy is in redu-
cing non-therapeutic laparotomies for patients with no
disease (38.9%) and in assessing patients with highburden of disease with high grade histology (61.1%),
allowing the disease to be down-staged with systemic
chemotherapy. An important finding was that many
patients with extensive disease who were excluded by
DL were able to subsequently undergo CRS + HIPEC
after the downgrading of their disease by chemotherapy
(5 out 11 patients with extensive disease excluded
by DL) (Figure 1).
Based on our institutional practice, a diagnostic laparos-
copy was not routinely utilized in patients with low-grade
disease such as DPAM unless concerns for completion of
cytoreduction were present, or in patients with bowel ob-
struction and in patients with a hostile abdomen, which
does constitute a significant proportion of patients in a
practice at a peritoneal surface malignancy center.
Oncological concerns of a laparoscopy include incom-
plete assessment of the peritoneal cavity and port site
recurrences. In our study, we found that we were able to
assess the PCI score more as a threshold rather than for
accuracy. We recognize that open assessment of the
Figure 1 Flowchart depicting the outcomes of diagnostic laparoscopy (DL). CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal
chemotherapy.
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for the right hemidiaphragm, omental bursa and the pel-
vis, yet believe that an assessment of high burden of dis-
ease is easily feasible with a laparoscopy.
Patients selected for HIPEC often belong to advanced
age groups associated with poor performance status
resulting in increased morbidity rates [27,28]. The peri-
toneal carcinomatosis index is a well-validated tool of
prognostic significance for assessing the burden of peri-
toneal disease and is used for selecting patients for CRS
+HIPEC [7]. The sensitivity of cross-sectional imaging
to accurately describe peritoneal carcinomatosis remainsFigure 2 Flowchart depicting the outcomes of patients who did not u
hyperthermic intraperitoneal chemotherapy; DPAM, disseminated peritonealow despite the recent advancements [16,20,29,30]. As
many as 20 to 40% of the patients considered eligible for
HIPEC based on imaging are excluded from HIPEC at
laparotomy [17,18]. Such non-therapeutic laparotomies
may adversely affect the outcome of this vulnerable
population with short life period, as well as affecting the
physician patient relationship, thereby supporting the
use of a diagnostic laparoscopy.
The use of laparoscopy in PC has hitherto remained
limited due to technical concerns that the adhesions from
cancer and past surgeries may hinder adequate assess-
ment and possibly result in an increased rate ofndergo diagnostic laparoscopy. CRS, cytoreductive surgery; HIPEC,
l adenomucinosis.
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cessful in a majority (89.2%) of the patients and was not
associated with any complications.
All patients underwent advanced imaging (triple phase
helical CT scans/MRI) routinely before the surgical
evaluation for HIPEC. All outside images were also
reviewed at the institute. Therefore the high rate of ex-
clusion from CRS +HIPEC (28.4%) reflects the low fidel-
ity of imaging for classifying patients for CRS + HIPEC.
This is lower than the exclusion rates reported for gall-
bladder cancer and also for pancreatic cancer in the pre-
neoadjuvant paradigm and could be attributed to the
good quality cross-sectional imaging [16,19,20,30,32,33].
The fact that many of these patients were referred from
outside following incidental diagnosis for peritoneal car-
cinomatosis during surgery for primary tumor and had
adequate EL evaluation may also have contributed to the
lower rate of exclusion from curative surgery.
Use of laparoscopy for staging may permit its exten-
sion to performing HIPEC when feasible. In the group of
patients evaluated for this study, CC0 cytoreduction
followed by successful HIPEC was achieved laparoscop-
ically in nine patients. Other groups have also reported
the feasibility of laparoscopic HIPEC [21]. Since most of
the patients would need to continue chemotherapy after
HIPEC, a laparoscopic procedure may permit lowering
of this convalescent period to chemotherapy with poten-
tial impact on the outcome.
The routine use of laparoscopy has significant financial
implications as well since the laparoscopy adds to the
overall cost of therapy. In a previous paper, we studied
the cost effectiveness of laparoscopy in pancreatic cancer
and demonstrated that laparoscopy was cost-effective at
high probability for exclusion from resection [33]. This
is directly related to pretest probability for exclusion as
well as the sensitivity of laparoscopy. which may be sub-
jective to the surgeon and influenced by the experience.
The use of imaging modalities like diffusion-weighted
MRI and PET scanning for the identification of peritoneal
disease is evolving but may increase the cost differential
dramatically. These modalities were used during diagno-
sis and follow-up of the patients, but the sensitivity of
these modalities is yet to be validated. The radiological
evaluation permits only anatomic characterization of the
extent of the disease whereas laparoscopy permits patho-
logical diagnosis as well with potential prognostic value.
A potential limitation of the study is that the sample
was small in size and taken from a single institution.
The study may suffer from confounding biases inherent
to the observational study design. In addition, we did
not formally correlate the laparoscopic PCI with an open
PCI, although we believe that a laparoscopic PCI would
under-stage rather than over-stage someone with disease
and thus not alter the algorithms proposed.Conclusions
Laparoscopy is feasible in patients with peritoneal car-
cinomatosis who are expected to undergo cytoreductive
surgery. It can filter out ineligible patients with either no
carcinomatosis or extensive disease precluding complete
cytoreduction during CRS + HIPEC. Technical and
oncological concerns of performing a laparoscopy were
underwhelming based on our study.
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